Going 0-for-4 on a big PhIII program, Novartis scraps their top asthma prospect and signals big trouble for a little biotech
Novartis this morning reported that their asthma drug fevipiprant flunked two more Phase III studies, crushing their hopes in what had been a star H2 development program at the pharma giant.
Back in October Novartis buried the news that fevipiprant had failed the first 2 Phase III studies in their Q3 report, noting a lack of success in scoring an improvement in FEV1 among moderate patients. But the pharma giant immediately shifted focus to LUSTER 1 and 2 in moderate to severe patients, noting that they were the core studies needed for registration and a blockbuster future.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.